175 related articles for article (PubMed ID: 36861458)
1. Guidance on using real-world evidence from Western Europe in Central and Eastern European health policy decision making.
Németh B; Kamusheva M; Mitkova Z; Petykó ZI; Zemplényi A; Dimitrova M; Tachkov K; Balkányi L; Czech M; Dawoud D; Goettsch W; Hren R; Knies S; Lorenzovici L; Maravic Z; Piniazhko O; Zerovnik S; Kaló Z
J Comp Eff Res; 2023 Apr; 12(4):e220157. PubMed ID: 36861458
[No Abstract] [Full Text] [Related]
2. Using real-world evidence in healthcare from Western to Central and Eastern Europe: a review of existing barriers.
Kamusheva M; Németh B; Zemplényi A; Kaló Z; Elvidge J; Dimitrova M; Pontén J; Tachkov K; Mitkova Z
J Comp Eff Res; 2022 Aug; 11(12):905-913. PubMed ID: 35726611
[TBL] [Abstract][Full Text] [Related]
3. Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges.
Daubner-Bendes R; Kovács S; Niewada M; Huic M; Drummond M; Ciani O; Blankart CR; Mandrik O; Torbica A; Yfantopoulos J; Petrova G; Holownia-Voloskova M; Taylor RS; Al M; Piniazhko O; Lorenzovici L; Tarricone R; Zemplényi A; Kaló Z
Front Public Health; 2020; 8():612410. PubMed ID: 33490024
[No Abstract] [Full Text] [Related]
4. Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment.
Zemplényi A; Tachkov K; Balkanyi L; Németh B; Petykó ZI; Petrova G; Czech M; Dawoud D; Goettsch W; Gutierrez Ibarluzea I; Hren R; Knies S; Lorenzovici L; Maravic Z; Piniazhko O; Savova A; Manova M; Tesar T; Zerovnik S; Kaló Z
Front Public Health; 2023; 11():1088121. PubMed ID: 37181704
[TBL] [Abstract][Full Text] [Related]
5. Recommendations for patient involvement in health technology assessment in Central and Eastern European countries.
Jakab I; Dimitrova M; Houÿez F; Bereczky T; Fövényes M; Maravic Z; Belina I; Andriciuc C; Tóth K; Piniazhko O; Hren R; Gutierrez-Ibarluzea I; Czech M; Tesar T; Niewada M; Lorenzovici L; Kamusheva M; Manova M; Savova A; Mitkova Z; Tachkov K; Németh B; Petykó ZI; Dawoud D; Delnoij D; Knies S; Goettsch W; Kaló Z
Front Public Health; 2023; 11():1176200. PubMed ID: 37465169
[TBL] [Abstract][Full Text] [Related]
6. Can we use existing guidance to support the development of robust real-world evidence for health technology assessment/payer decision-making?
Capkun G; Corry S; Dowling O; Asad Zadeh Vosta Kolaei F; Takyar S; Furtado C; Jónsson P; Kleinermans D; Lambert L; Schiel A; Facey K
Int J Technol Assess Health Care; 2022 Nov; 38(1):e79. PubMed ID: 36321447
[TBL] [Abstract][Full Text] [Related]
7. Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions.
Deverka PA; Douglas MP; Phillips KA
Value Health; 2020 May; 23(5):540-550. PubMed ID: 32389218
[TBL] [Abstract][Full Text] [Related]
8. Implementation of coverage with evidence development schemes for medical devices: A decision tool for late technology adopter countries.
Kovács S; Kaló Z; Daubner-Bendes R; Kolasa K; Hren R; Tesar T; Reckers-Droog V; Brouwer W; Federici C; Drummond M; Zemplényi AT
Health Econ; 2022 Sep; 31 Suppl 1(Suppl 1):195-206. PubMed ID: 35322478
[TBL] [Abstract][Full Text] [Related]
9. HTA Implementation Roadmap in Central and Eastern European Countries.
Kaló Z; Gheorghe A; Huic M; Csanádi M; Kristensen FB
Health Econ; 2016 Feb; 25 Suppl 1(Suppl Suppl 1):179-92. PubMed ID: 26763688
[TBL] [Abstract][Full Text] [Related]
10. Use of real-world evidence for oncology clinical decision making in emerging economies.
Petracci F; Ghai C; Pangilinan A; Suarez LA; Uehara R; Ghosn M
Future Oncol; 2021 Aug; 17(22):2951-2960. PubMed ID: 34044583
[TBL] [Abstract][Full Text] [Related]
11. Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative.
Orsini LS; Monz B; Mullins CD; Van Brunt D; Daniel G; Eichler HG; Graff J; Guerino J; Berger M; Lederer NM; Jonsson P; Schneeweiss S; Wang SV; Crown W; Goettsch W; Willke RJ
Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1504-1513. PubMed ID: 32924243
[TBL] [Abstract][Full Text] [Related]
12. Real-World Evidence to Inform Regulatory Decision Making: A Scoping Review.
Jansen MS; Dekkers OM; le Cessie S; Hooft L; Gardarsdottir H; de Boer A; Groenwold RHH
Clin Pharmacol Ther; 2024 Jun; 115(6):1269-1276. PubMed ID: 38390633
[TBL] [Abstract][Full Text] [Related]
13. Data Governance for Real-World Data Management: A Proposal for a Checklist to Support Decision Making.
Solà-Morales O; Sigurðardóttir K; Akehurst R; Murphy LA; Mestre-Ferrandiz J; Cunningham D; de Pouvourville G
Value Health; 2023 Apr; 26(4S):32-42. PubMed ID: 36870678
[TBL] [Abstract][Full Text] [Related]
14. The transferability of health technology assessment: the European perspective with focus on central and Eastern European countries.
Németh B; Goettsch W; Kristensen FB; Piniazhko O; Huić M; Tesař T; Atanasijevic D; Lipska I; Kaló Z
Expert Rev Pharmacoecon Outcomes Res; 2020 Aug; 20(4):321-330. PubMed ID: 32500749
[TBL] [Abstract][Full Text] [Related]
15. Using Real-World Data in the Health Technology Assessment of Pharmaceuticals: Strengths, Difficulties, and a Pragmatic Way Forward.
Akehurst R; Murphy LA; Solà-Morales O; Cunningham D; Mestre-Ferrandiz J; de Pouvourville G
Value Health; 2023 Apr; 26(4S):11-19. PubMed ID: 36706952
[TBL] [Abstract][Full Text] [Related]
16. What, Where, and How to Collect Real-World Data and Generate Real-World Evidence to Support Drug Reimbursement Decision-Making in Asia: A reflection Into the Past and A Way Forward.
Kc S; Lin LW; Bayani DBS; Zemlyanska Y; Adler A; Ahn J; Chan K; Choiphel D; Genuino-Marfori AJ; Kearney B; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Akmal Shafie A; Sui B; Suwantika A; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Teerawattananon Y; Wee HL
Int J Health Policy Manag; 2023; 12():6858. PubMed ID: 37579427
[TBL] [Abstract][Full Text] [Related]
17. Advancing the use of real world evidence in health technology assessment: insights from a multi-stakeholder workshop.
Claire R; Elvidge J; Hanif S; Goovaerts H; Rijnbeek PR; Jónsson P; Facey K; Dawoud D
Front Pharmacol; 2023; 14():1289365. PubMed ID: 38283835
[No Abstract] [Full Text] [Related]
18. Study types and reliability of Real World Evidence compared with experimental evidence used in Polish reimbursement decision-making processes.
Wilk N; Wierzbicka N; Skrzekowska-Baran I; Moćko P; Tomassy J; Kloc K
Public Health; 2017 Apr; 145():51-58. PubMed ID: 28359391
[TBL] [Abstract][Full Text] [Related]
19. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
Zelei T; Molnár MJ; Szegedi M; Kaló Z
Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
[TBL] [Abstract][Full Text] [Related]
20. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
